Power Law company profile

Neuren Pharmaceuticals

Biotech & Life Sciences · Melbourne, Australia · Founded 2001 · IPO 2005 Unicorn

Developing new therapies for neurodevelopmental disorders with high unmet need

Valuation

$828M

Market cap · May/2026

Revenue

$42M

Latest reported FY

EBITDA

$7.4M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Global footprint

Where Neuren Pharmaceuticals has talent and traffic

Workforce by country

2 countries with
team presence

🇦🇺 Australia81.2%

🇺🇸 United States18.8%

2 countries shown

Market sentiment

What the market is saying about Neuren Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Neuren Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neuren Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles